Home > Financial Ratios > CORONA REMEDIES

CORONA REMEDIES
Core EBITDA Growth

    Back to All Ratios
CORONA REMEDIES is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
COMMUNITY POLL
for CORONA REMEDIES
Please provide your vote to see the results

CORONA REMEDIES Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2026Mar2025Mar2024Mar2023
   Core EBITDA Growth(%) 23.6652.5619.37-

What is the latest Core EBITDA Growth ratio of CORONA REMEDIES ?

The latest Core EBITDA Growth ratio of CORONA REMEDIES is 23.66 based on Mar2026 Consolidated results.
Year Core EBITDA Growth
Mar202623.66
Mar202552.56
Mar202419.37
Mar2023-

How is Core EBITDA Growth of CORONA REMEDIES Trending?

Years Core EBITDA Growth % Change
Mar2026 23.66
-54.98
Mar2025 52.56
171.35
Mar2024 19.37
0
Mar2023 0 -

Other Financial Ratios of CORONA REMEDIES


Compare Core EBITDA Growth ratio of peers of CORONA REMEDIES

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
CORONA REMEDIES ₹13,456.4 Cr -1.7% 3.5% NA Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹440,398.0 Cr -0.4% -3.3% 15.5% Stock Analytics
DIVIS LABORATORIES ₹248,664.0 Cr 0.4% 9.9% 55.1% Stock Analytics
TORRENT PHARMACEUTICALS ₹182,738.0 Cr -3.4% -4.2% 37.1% Stock Analytics
CIPLA ₹110,794.0 Cr 0.5% -3.2% -12.8% Stock Analytics
DR REDDYS LABORATORIES ₹97,749.4 Cr 0.9% 0% -11% Stock Analytics


CORONA REMEDIES Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
CORONA REMEDIES

-1.7%

3.5%

NA
SENSEX

-0.8%

-3.8%

-8.9%


You may also like the below Video Courses